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Abstract: Background: Over the next 20 years, oropharyngeal cancers (OPC) will represent the
majority of head and neck cancers (HNCs) in the United States. It is estimated that human
papillomavirus (HPV) may account for as much as 70% to 80% of OPCs in North America and
in certain parts of Europe. It is hence crucial to understand the disease risk factors and natural
history of oral HPV infections. We hypothesized that poor oral health (by measures such as poor oral
hygiene and periodontal disease) leads to a higher degree of oral HPV-16 infections within a patient
cohort from a dental school clinic. This study aims to test this hypothesis and gauge possible disease
associations before larger scale studies. Subjects and Methods: 223 participants were recruited in
this study from the University of Queensland Dental School clinic. Clinical oral health parameters
(such as oral hygiene measures and periodontal disease measurements) have been examined and
determined by dental professionals. We have collected oral rinse samples from these volunteers.
Results: 10 (4.5%) out of 223 participants were found to have HPV-16 DNA in their oral rinse samples
using NB2 endpoint PCR and Sanger sequencing. Within the HPV-16 DNA positive subjects, 7 (70%)
and 3 (30%) were associated with poor oral hygiene and periodontal disease, respectively. Conclusion:
Our results show a trend towards a positive correlation between oral HPV-16 infection and poor
clinical oral health status.
Keywords: human papillomavirus (HPV); oropharyngeal cancer; oral cancer; head and neck cancer;
saliva diagnostics; oral rinse; oral health; periodontal health; smoking; alcohol
1. Introduction
Over the next 20 years, oropharyngeal cancers (OPC) will represent the majority of head and
neck cancers (HNCs) in the United States [1], while oral cavity cancers (OC, mainly non-human
papillomavirus (HPV)-16) are increasing in emerging economies [2]. More than half of OPC and OC
tumours are diagnosed at an advanced stage [3], and only 50% of OC patients and 66% of OPC patients
survive beyond 5 years (American Cancer Society, 2015). Furthermore, 30% of OPC patients develop
recurrences and metastases within 2 years [2]. OPC is generally caused by oral or oropharyngeal
infection with HPV and, at any given time, approximately 7% of the population will have an oral or
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oropharyngeal HPV infection [4,5]. The lifetime oral HPV exposure rate is unknown, but an estimated
65%–100% of sexually active adults have been exposed to HPV at any anatomic site (oral, genital,
or anal) [6–8]. Men are more likely to have an oral HPV infection than women [4]. It is estimated
that HPV may account for as much as 70% to 80% of OPCs in North America and in certain parts of
Europe [8–10].
HPV is a double-stranded DNA virus, infects basal cells of the epithelium lining and has been
documented to cause various epithelial lesions. More than 30 genotypes of mucosotropic HPV
have been identified with low-risk types (most common 6, 11) being associated with benign lesions
and high-risk types (most common 16, 18) being associated with malignant conditions (such as
cervical malignancy and OPC) [11–13]. HPV-16-driven OPC constitute 90% of HPV-positive OPC [14].
The aetiology and risk factors of oral and oropharyngeal HPV infection remains controversial; however,
past studies have shown that these risk factors include oral sex, multiple sexual partners, poor oral
hygiene and immunodeficiency conditions [15–20]. Identifying key risk factors may help to improve
disease screening processes to identify high-risk individuals for developing OPC which may lead to
OPC prevention and improve disease mortality [21].
The oral cavity and oropharynx are lined with various types of specialised epithelia (i.e.,
mucosal squamous epithelium) [22]. Due to HPV’s known basal cell tropism, it is logical to
examine the epithelial components within these regions when studying HPV infections [22]. Previous
studies have shown that self-reported poor oral hygiene is an independent risk factor for high-risk
HPV infections [15,23]. The most common pathology involving oral epithelium is gingivitis—the
inflammation of gums. Gingivitis is a non-specific and reversible gingival inflammation in response to
oral plaque biofilms [24]. Untreated gingivitis in susceptible patients may progress to periodontitis
(the inflammation which features irreversible damage to the gingiva and supporting tissues of the
tooth, periodontium) of which the most common type is chronic periodontitis [24].
We hypothesised that poor clinical oral health (measures such as oral hygiene and periodontal
disease) leads to a higher degree of oral HPV-16 infections within this dental school patient population.
To test this hypothesis, we recruited participants (n = 223) with both good and bad oral hygiene and
determined their periodontal disease status, as well as other oral health parameters. This is the first
study to report clinical oral health parameters examined and evaluated by dental professionals and
not self-reported oral health status. We found that oral HPV-16 infection within the Australian Dental
study group is 4.5%. Our results demonstrated a positive correlation between oral HPV-16 infection
and poor oral health status.
2. Methods
2.1. Participants
A total of 223 patients attending The University of Queensland School of Dentistry (UQDS)
Clinic between October 2014 and October 2015 were recruited as study participants (see Table 1). All
participants provided informed consent prior to the study which was approved by the UQ medical
research ethics committee (Approval number 2014000862, 22 July 2014), and Queensland University
of Technology (QUT) university human research ethics committee (Approval number 1400000641,
11 September 2014). Both approvals were obtained in 2014. The study was performed in accordance
with the Declaration of Helsinki.
Participant inclusion criteria included (1) willingness to participate and provide written informed
consent; (2) never received HPV vaccination; (3) older than 18 years of age (to exclude disparities due
to sexual transmission of HPV) [15,25–27]; (4) no history of cancer and not receiving chemotherapy or
radiation therapy, (malignancies and their treatment profoundly affect oral health status and immune
status, which may increase HPV infection rates compared to general population rates) [15,25–28];
(5) no history of diabetes mellitus, cardiovascular diseases, blood disorders, xerostomia and any other
Diagnostics 2017, 7, 11 3 of 10
systemic conditions that may affect oral health status) [15,25–27,29]; (6) not on current medication;
(7) at least 20 teeth in the mouth, to evaluate the effect of periodontal infection on oral HPV infection.
2.2. Participant Demographics, Lifestyle and Clinical Data
Participant demographic information included in this study was collected for gender, age
and race (see Supplementary Tables S1 and S2). Participant lifestyle factors such as smoking and
alcohol consumption status were recorded. Participants’ race was classified as Caucasian, Asian,
South Asian, Aborigine or Pacific Islander, African, Latino and other ethnicity groups. Participant
smoking status was recorded based on the Centre of Disease Control smoking classification as follows:
never smoked; former smoker; current daily smoker (1–15 cigarettes/day); current daily smoker
(25–34 cigarettes/day); current daily smoker (>35 cigarettes/day); and current non-daily smoker
(<1 cigarettes/day) [30]. Participant alcohol consumption status was recorded based on the U.S. Centre
for Nutrition Policy and Promotions—Dietary Guidelines for Americans as follows: non-drinker,
infrequent drinker (<1 standard drinks/week), regular drinker (<1 standard drink per day, female;
<2 standard drinks per day, male), regular drinker (>1 standard drink per day, female; >2 standard
drinks per day, male) [31] All participant demographic and lifestyle measures were confirmed with
the participant verbally and recorded at the time of collection.
Participant clinical oral health measures were recorded, including plaque level, supra-gingival
calculus level, sub-gingival calculus level (all three parameters were graded as mild—detected on
less than 30% of the total number of teeth, moderate—detected on 30% to 60% of the total number of
teeth, and severe—detected on more than 60% of the total number of teeth), periodontal screening
record (PSR) (score 0–4, for each of six divided anatomical sextants in the mouth: score 0 = no
bleeding on probing (BOP) and calculus present, no periodontal pocket probing depth greater than
3.5 mm; score 1 = BOP present, no calculus present, no periodontal pocket probing depth greater
than 3.5 mm; score 2 = BOP and calculus present, no periodontal pocket probing depth greater than
3.5 mm; score 3 = BOP and calculus present, periodontal pocket probing depths greater than 3.5 mm
but less than 5.5 mm, score 4 = BOP and calculus present, periodontal pocket probing depths greater
than 5.5 mm) [32] and decayed, missing and filled teeth (DMFT) number (0–28). All oral health
measurements were extracted from participants’ most recent oral examination records at the UQDS, at
the time of sample collection; the measurement scores were determined by an operating training dentist
who conducted the oral examination and the findings were verified by a qualified supervising dentist.
Participants were grouped based on their periodontal disease status. If any of the six PSR
scores were greater than 3, the patient was classified as a periodontal-diseased patient [32]. If none
of the six PSR scores were greater than 2, the patient was classified as a non-periodontal-diseased
patient [32]. Participants were also grouped based on their oral hygiene status. If any of the plaque and
supra/sub-gingival calculus scores were greater than the moderate level, the participant was classified
as having poor to fair oral hygiene (as opposed to good to excellent oral hygiene).
2.3. Salivary Oral Rinse Sample Collection and Processing
Appropriate environmental controls and blinded blank saline samples were collected at the
UQDS to ensure that the sample are not contaminated by HPV-16 virus aerosols. Prior to sample
collection, participants were asked to rinse their mouths with water to remove any food debris and
other irrelevant material. Participants were then instructed to use 20 mL of 0.9% saline to swish and
gargle alternatively for 30 s (alternate every 5 s) and spit the sample into a sterile collection tube as per
our previous work [16,33]. The samples were then transported on dry ice and stored at −80 ◦C at QUT
adhering to local storage procedures and protocols, until further processed. Clinical and laboratory
staff were double-blinded through a process of sample de-identification in order to reduce the risk
of bias.
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2.4. DNA Extraction from Oral Rinse Samples
Oral exfoliated cell pellets were resuspended in sterile phosphate-buffered saline (PBS) and DNA
was extracted using the QIAmp DNA Mini Kit, Catalog number 51304 (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. DNA samples were assessed for purity and quantified
on a Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific, Pittsburgh, PA, USA) (see Figure 1).
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The specificity of NB2 primers was ascertained by isolating DNA from the PV-positive cell line
(SCC-2) and amplifying, followed by Sanger sequenceing identification (see Figure 1 and Supplemental
Figure S1).
The PCR setup consisted of 50 ng of DNA isolated from oral rinse samples, 1 µM of each primer,
1× Emerald AMP MAX HS PCR Mastermix (Takara Bio, Otsu, Shiga, Japan) in a final volume of
12.5 µL. PCR cycling consisted of an initial denaturation at 95 ◦C for 3 min followed by 40 cycles
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Terminator v3.1 Cycle Sequencing Kit Catalog nu ber: 4337458 (Ther o Fisher Scientific, altha ,
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Genetics Research Centre, University of Queensland. Specifically, BigDye sequencing reactions were
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electrophoresis and fluorescence detection of cleaned-up reactions were done on either a 3130XL or
3730 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). Sanger sequencing results from
NB2 amplicons were analysed using the Standard Nucleotide—Basic Local Alignment Search Tool
(BLAST) on the National Centre for Biotechnology Information (NCBI) website to confirm HPV-16
homology (see Supplemental Figure S2).
2.6. Statistical Methods
In order to examine the potential association between oral health and HPV-16 infection, HPV-16
DNA positivity results were analyzed against patient oral health status and periodontal disease
status, as well as other recorded individual parameters (plaque, supra/sub-gingival calculus levels,
gender, age, race, smoking and alcohol consumption status), using Fisher’s exact test. IBM SPSS
v22 (IBM Corp, Armonk, NY, USA) was used as data analysis software. Fisher’s exact method
was used to obtain p-values (exact significance, 1-sided) for variables with 2 × 2 contingency tables
(gender, oral health status, periodontal status); for variables with contingency tables greater than
2 × 2 (plaque, supra/sub-gingival calculus levels, age, race, smoking and alcohol consumption status),
Monte Carlo method (confidence level 99%, sample = 10,000) was used to obtain p-values (Monte
Carlo significance, 2-sided). p-values less than 0.05 were considered significant. If the p value for a
specific variable was significant, post-hoc testing was performed to determine p-values for each group
within the variable. A significant p-value indicated that a specific sub-group within each variable was
significantly associated with HPV-16.
3. Results
3.1. Patient Demographics
Participants (n = 223) were recruited from UQDS. Ten (4.5%) of these participants were confirmed
to be HPV-16 DNA positive using NB2 endpoint PCR followed by Sanger sequencing confirmation.
Participants had a median age of 41 years and were distributed such that 53 participants (23.8%)
were 18–30 years old, 106 (47.5%) subjects were 31–50 years old, 60 (26.9%) subjects were 51–70 years
old, 4 (1.8%) were 71–90 years old. While more male 137 (61.4%) than female 86 (38.6%) participants
were recruited, the age and gender differences between participants were not statistically significant.
Demographically, 166 (78.3%) participants were identified as Caucasians, 26 (12.3%) Asians, 10 (4.7%)
South Asians, 4 (1.9%) Aborigine or Pacific Islanders, 1 (0.5%) African, 4 (1.9%) Latino and 1 (0.5%)
other race.
3.2. Lifestyle Related Risk Factors/Parameters
The prevalence of daily smoking amongst participants was 19.0%, which favorably compared with
previous data from a similar UQDS population (22.9%) [34]. A significant proportion of participants
were identified as former smokers (33.0%). Four out of the ten HPV-16 DNA positive participants
did not disclose their smoking status. As such, any association between smoking and HPV-16 DNA
infection could not be ascertained.
More than half (52.1%) of recruited participants were identified as regular consumers of alcohol,
with 10.6% consuming more than one or two standard drinks per day. In total, 35 participants did not
disclose their alcohol consumption patterns. A broad variation of alcohol consumption habits was
noted amongst both HPV-16 DNA positive and HPV-16 negative participants. Neither frequency nor
engagement in infrequent or frequent alcohol consumption were found to be associated with HPV-16
DNA prevalence (p = 0.147).
3.3. Oral Health Parameters
Almost all participants recruited demonstrated some level of plaque retention (98.6%). Supra
(98.6%) and sub-gingival (90.0%) calculus presence was a common clinical finding amongst recruited
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participants. Neither the presence nor severity of these clinical parameters of gingival health was
associated with HPV-16 DNA prevalence. Participants were also categorised based on their DMFT
score. Of the study cohort, 35.9% (79) had a low measure of dental decay (past/present), whilst 42.7%
(94) of participants experienced a moderate level of DMFT and 21.4% (47) of participants recorded a
high score of DMFT. Nevertheless, DMFT score was not significantly associated with HPV-16 DNA
infection (p = 0.259). While periodontal disease status was not significantly associated with the presence
of HPV-16 DNA (p = 0.367), a large periodontal disease burden (40.5%) was noted within the recruited
participants requiring further dental assistance.
Of the 10 HPV-positive participants, four patients presented with mild plaque build-up whilst six
participants presented with moderate plaque build-up. Based on the aforementioned criteria, three
participants presented with good to excellent oral hygiene whilst seven presented with poor to fair oral
hygiene. Although the trends concur with our hypothesis, we did not find a statistically significant
association between clinical oral health parameters and HPV-16 DNA prevalence status (Table 1).
Table 1. Participant demographic and clinical parameters vs. human papillomavirus (HPV)-16 DNA
status using oral rinse samples. DMFT, decayed, missing and filled teeth.
Variable
HPV-16 DNA
Positive (% within
Variable)
HPV-16 DNA
Negative (% within
Variable)
Total Number
(% within Total
Population)
p-Value
Gender
0.328Male 5 (3.6) 132 (96.4) 137 (61.4)
Female 5 (5.8) 81 (94.2) 86 (38.6)
Age
0.130
18–30 1 (1.9) 52 (98.1) 53 (23.8)
31–50 3 (2.8) 103 (97.2) 106 (47.5)
51–70 6 (10.0) 54 (90.0) 60 (26.9)
71–90 0 (0) 4 (100.00) 4 (1.8)
Race
1.000
Caucasian 6 (3.6) 160 (96.4) 166 (78.3)
Asian 0 (0) 26 (100.0) 26 (12.3)
South Asian 0 (0) 10 (100.0) 10 (4.7)
Aborigine/Pacific Islander 0 (0) 4 (100.0) 4 (1.9)
African 0 (0) 1 (100.0) 1 (0.5)
Latino 0 (0) 4 (100.0) 4 (1.9)
Other 0 (0) 1 (100.0) 1 (0.5)
Smoking
0.595
Never Smoker 2 (2.1) 95 (97.9) 97 (45.8)
Former Smoker 4 (5.7) 66 (94.3) 70 (33.0)
Current Daily Smoker <15 0 (0) 26 (100.00) 26 (12.3)
Current Daily Smoker 15–24 0 (0) 12 (100.0) 12 (5.7)
Current Daily Smoker 25–34 0 (0) 1 (100.0) 1 (0.5)
Current Daily Smoker >35 0 (0) 1 (100.0) 1 (0.5)
Current Non Daily Smoker 0 (0) 5 (100.0) 5 (2.4)
Alcohol consumption
0.147
Non Drinker 1 (1.8) 54 (98.2) 55 (29.3)
Infrequent Drinker 3 (8.6) 32 (91.4) 35 (18.6)
Regular Drinker (<1/day for F, <2/day for M) 1 (1.3) 77 (98.7) 78 (41.5)
Regular Drinker (>1/day for F, >2/day for M) 1 (5.0) 19 (95.0) 20 (10.6)
Plaque
0.262
Nil 0 (0) 3 (100.0) 3 (1.4)
Mild 4 (3.6) 108 (96.4) 112 (50.9)
Moderate 6 (8.1) 68 (91.9) 74 (33.6)
Severe 0 (0) 31 (100.0) 31 (14.1)
Calculus (Supra-gingival)
0.182
Nil 0 (0) 3 (100.0) 3 (1.4)
Mild 2 (1.9) 106 (98.1) 108 (49.1)
Moderate 6 (7.3) 76 (92.7) 82 (37.3)
Severe 2 (7.4) 25 (92.6) 27 (12.3)
Calculus (Sub-gingival)
0.608
Nil 1 (4.5) 21 (95.5) 22 (10.0)
Mild 3 (3.1) 95 (96.9) 98 (44.5)
Moderate 4 (5.6) 68 (94.4) 72 (32.7)
Severe 2 (7.1) 26 (92.9) 28 (12.7)
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Table 1. Cont.
Variable
HPV-16 DNA
Positive (% within
Variable)
HPV-16 DNA
Negative (% within
Variable)
Total Number
(% within Total
Population)
p-Value
Oral Hygiene
0.233Good to Excellent 3 (2.9) 99 (97.1) 102 (46.4)
Poor to Fair 7 (5.9) 111 (94.1) 118 (53.6)
DMFT
0.259
0–9 6 (7.6) 73 (92.4) 79 (35.9)
10–19 2 (2.1) 92 (97.9) 94 (42.7)
20–28 2 (4.3) 45 (95.7) 47 (21.4)
Periodontal Status
0.367Non-Periodontal-Diseased 7 (5.3) 124 (94.7) 131 (59.5)
Periodontal Diseased 3 (3.4) 86 (96.6) 89 (40.5)
4. Discussion
This is one of the first HPV studies to use oral health parameters examined and reported by dental
professionals. In our study, the prevalence of HPV-16 DNA was found to be 4.5%, a rate comparable
to previous studies by Gillison et al. (6.9%) and Antonsson et al. (2.3%) [4,35]. Men showed a lower
HPV-16 infection rate (3.6%) than women (5.8%). Albeit not being statistically significant, our results
showed a positive correlation between oral HPV-16 infection and poor oral hygiene. There was no
statistically significant association found between HPV-16 DNA detection and socio-demographic or
clinical oral health parameters.
A range of potential risk factors for oral HPV-16 infections, such as close contact with HPV-positive
parents during early childhood [12], or maternal cervical/vaginal contact with a HPV-positive mother
during birth [36] have been proposed. In addition, it is widely accepted that oral sexual activities are
an established risk factor for HPV-16 infection [15,25–28,37–39]. In the current study, no social history
and/or history of oral sex activities were collated. In a previous study, Bui et al. [15] observed an
association between self-reported poor oral health and the risk of HPV-16 infection. An important
differentiation factor between our study and the latter work is the distinction between clinically
measured oral health parameters in our study as opposed to self-reported subjective oral health
measures reported by Bui et al. The latter researchers also found self-reported oral health status to
be an independent risk factor for oral HPV infection (OR = 1.55; 95% CI, 1.15–2.09). Similar trends of
odds ratios were observed in our study between clinical oral hygiene status and HPV-16 infections
(OR = 2.08; 95% CI, 0.52–8.27), though the wide confidence interval reflects the relatively low incidence
of infection, and smaller sample size, in the present study.
It has been suggested by Tezal et al. that oral HPV infections may modify periodontal disease, and
interact in a complex manner [28,36,40]. It has been proposed that instead of periodontal infections
creating a suitable niche for oral HPV infections, it is also possible that oral HPV infection will
exacerbate periodontal diseases [28,36]. Although gingivitis is an essential precursor for chronic
periodontitis, not all gingivitis patients progress to chronic periodontitis, irrespective of the extent and
duration of disease [28]. Multiple theories have been proposed for this two-way process of disease
transformation, apart from the commonly accepted theory that periodontal patients elicit a different
immune response due to their genetic predisposition [28,41]. One of these is that multi-organism
synergy may play a role in the disease transformation process [28]. Virus-induced immunological
responses may cause an imbalance between the host and pathogen, resulting in gingivitis–periodontitis
transformation [28,41]. Additionally, HPV infection causes a cellular defect known as koilocytosis [39],
whereby fragile defective cells may be more prone to potential periodontal breakdown [39,41].
Therefore, a model of the interaction between the two disease entities may be much more complex
than hitherto envisioned and remains to be elucidated.
The major limitations in our study are the sample size. It is likely insufficient to detect a significant
increase in HPV-16 infection associated with poor oral hygiene, as a minimum sample size of 150 per
group would have been required for this purpose (power = 0.90, α = 0.05, anticipated detection rate
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in good oral hygiene group = 0.02). Another important consideration regarding the participants of
this study is that the majority are patients who required treatment due to active oral disease within a
university clinic setting. Consequently, the prevalence of poor oral hygiene and dental and periodontal
infection in the study participants was not necessarily reflective of the general population in Australia.
5. Conclusions
In our pilot study population, the prevalence of HPV-16 DNA was found to be 4.5%. The results
from this study highlight a positive correlation between oral HPV infection and poor hygiene, which
has previously been documented to be an independent risk factor of HPV infection. Future studies with
a larger study population (including healthy controls with premalignant disease as well as people with
chronic inflammation) with active clinical oral health parameters may yield significant results. It has
been advocated that general dental practitioners should advise patients about oral sexual behavior and
HPV infection risk. However, for this practice to become part of routine dental consultative practices,
many cultural and social hurdles need to be overcome [42] and clear evidence linking poor oral health
to HPV infection needs to be presented.
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